Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic

Comparative Efficacy of Topical Salicylic Acid/Lactic Acid, Intralesional Candida Antigen, and Their Combination in the Treatment of Warts: A Randomized, Assessor-Blinded, Controlled Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07329907

Acronym

CA-SA/LA

Enrollment

126

Registered

2026-01-09

Start date

2023-12-01

Completion date

2024-12-30

Last updated

2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Papilloma Virus (HPV), Warts

Keywords

warts, verruca, candida antigen, intralesional immunotherapy, salicylic acid, lactic acid

Brief summary

Objective: To compare the efficacy, safety, and recurrence rates of topical salicylic acid/lactic acid (SA/LA) monotherapy (Group A), intralesional Candida antigen (CA) monotherapy (Group B), and their combination (Group C) for the treatment of warts.

Interventions

DRUGSalicylic Acid/Lactic Acid Topical Solution

Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.

BIOLOGICALCandida Antigen Intralesional Injection

Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.

COMBINATION_PRODUCTCandida Antigen and Salicylic Acid/Lactic Acid

Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Masking description

Assessor-Blinded (Outcome Assessor Only)

Eligibility

Sex/Gender

ALL

Age

5 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Single or multiple warts. 2. Aged 5 to 60 years. 3. Eligible for both topical and intralesional treatments. 4. No prior wart treatment for at least 1 month.

Exclusion criteria

1. Pregnancy or lactation. 2. Immunosuppression or use of immunosuppressive drugs. 3. Known sensitivity to study ingredients. 4. Systemic/local inflammation or infection. 5. History of bleeding/clotting disorder, or use of anticoagulants/NSAIDs. 6. History of asthma, allergic skin disorders, or convulsions. 7. History of chronic systemic diseases (renal/hepatic failure, cardiovascular disorders).

Design outcomes

Primary

Measure	Time frame	Description
Complete Response (CR) Rate	3 months post-treatment	Percentage of patients achieving complete disappearance of all warts.

Secondary

Measure	Time frame	Description
Distant Wart Clearance Rate	3 months post-treatment	Percentage of patients achieving clearance of non-injected/distant warts.
Recurrence Rate	6 months post-treatment	Percentage of patients with recurrence of warts after achieving CR.
Safety and Tolerability Profile	At each visit (every 2 weeks) and 3 months post-treatment	Incidence and severity of local (pain, edema, crustations) and systemic (flu-like symptoms) side effects.

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORGhada Shams

Benha University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026